CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on leveraging the DNA damage response to personalize breast cancer treatment. It aims to identify genetic markers that predict individual responses to therapies, particularly targeting cancers with specific DNA repair deficiencies.
We will exploit the DNA damage response (DDR) to assess and predict individual susceptibility and response focussed on breast cancer and breast cancer therapies.
The 1st targeted therapy based on the DDR is inhibition of PARP by olaparib, which induces synthetic lethality in cancer cells with a specific DDR defect.
Our members discovered olaparib, which is currently in Phase II trials.
Its use in DDR deficient cancers represents a truly personalised healthcare approach.
Due to the complexity of…
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom, Cambridge
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Cambridge
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
